Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan

Resection is the only curative treatment for pancreatic ductal adenocarcinoma (PDAC). Although the outcome of technically resectable PDAC has improved with advances in surgery and adjuvant therapy, the 5-year survival rate remains low at 20% to 40%. More effective therapy is needed. Almost 15 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Ei, Shigenori, Takahashi, Shinichiro, Ogasawara, Toshihito, Mashiko, Taro, Masuoka, Yoshihito, Nakagohri, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502496/
https://www.ncbi.nlm.nih.gov/pubmed/36843421
http://dx.doi.org/10.5009/gnl220311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502496/
https://www.ncbi.nlm.nih.gov/pubmed/36843421
http://dx.doi.org/10.5009/gnl220311

Ejemplares similares